Russian Federation offers Indonesia access to Sputnik V vaccine for COVID-19

Russian coronavirus vaccine Gam-COVID-Vac trade-named Sputnik V

The eastern city of Jiaxin's center for disease control and prevention (CDC) said in a statement on WeChat that two doses of the vaccine candidate, called CoronaVac, will cost 200 yuan ($29.75) per dose and that vaccinations for key groups including medical professionals have begun.

"They [Sinovac] said they will be meeting the Ethics Board this week", Domingo said.

A vaccine developed by the Vector State Virology and Biotechnology Centre in Siberia has been registered, President Vladimir Putin said in televised comments on Wednesday (Oct 14).

Several companies are also using this approach to develop a vaccine, including US companies Moderna and Pfizer whose candidates have reached late-stage trials.

"The Russian vaccine is already in Venezuela, tests have begun, there are already 2,000 volunteers", Maduro said.

The COVID-19 vaccine manufactured in China has passed the first of the three stages of review required to hold a clinical trial in the country. Even so, Deputy Prime Minister Tatyana Golikova said it is safe and the first 60,000 doses will be produced soon.

Since the start of the coronavirus pandemic, more than 23,000 people have died in Russian Federation from COVID-19 and it ranks fourth in the world for confirmed infections after the U.S., India and Brazil.

It has seen its number of new infections more than double within a month and set single-day records in each of the past six days.

That vaccine, known popularly as Sputnik V, has been met with skepticism both inside and outside of Russian Federation.

There is no internationally-approved vaccine to protect against COVID-19, which has killed more than 1 million people around the world and triggered economic chaos.

The DOST chairs the sub-TWG on Covid-19 vaccine development which includes other government agencies such as the DOH, the Department of Foreign Affairs (DFA), and the Department of Trade and Industry (DTI). The DOH will also lead in the communication campaign for the vaccine clinical trials to be conducted. Johnson & Johnson ordered a temporary halt in its late-stage trial this week after a patient became ill, while AstraZeneca has paused testing in the United States since early September after a patient came down with unexplained neurological symptoms. The head of Rospotrebnadzor, Ms Anna Popova, said she already received the inoculation and felt no side effects.

Sputnik V has been made available to people in at-risk groups, such as such as doctors and teachers, while tests are ongoing.

Related:

Comments


Other news